Edition:
India

Clovis Oncology Inc (CLVS.OQ)

CLVS.OQ on NASDAQ Stock Exchange Global Select Market

54.93USD
17 Jan 2018
Change (% chg)

-- (--)
Prev Close
$54.93
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
443,847
52-wk High
$99.45
52-wk Low
$45.42

Chart for

About

Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company's product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine... (more)

Overall

Beta: 1.61
Market Cap(Mil.): $4,124.93
Shares Outstanding(Mil.): 48.88
Dividend: --
Yield (%): --

Financials

BRIEF-Rucaparib MAA Referred By CHMP To Scientific Advisory Group On Oncology For Review

* RUCAPARIB MAA FOR THE OVARIAN CANCER TREATMENT INDICATION REFERRED BY CHMP TO SCIENTIFIC ADVISORY GROUP ON ONCOLOGY FOR REVIEW EXPECTED IN FEBRUARY 2018

19 Dec 2017

BRIEF-Clovis Announces Priority Review Designation For Rucaparib Supplemental NDA

* CLOVIS ANNOUNCES PRIORITY REVIEW DESIGNATION FOR RUCAPARIB SUPPLEMENTAL NEW DRUG APPLICATION

06 Dec 2017

BRIEF-Clovis Oncology reports Q3 adjusted shr loss of $1.24

* CLOVIS ONCOLOGY ANNOUNCES THIRD QUARTER 2017 OPERATING RESULTS

02 Nov 2017

BRIEF-Clovis Oncology submits supplemental New Drug Application for rucaparib

* Clovis Oncology submits supplemental New Drug Application for rucaparib as maintenance treatment for patients with platinum-sensitive recurrent ovarian cancer

10 Oct 2017

BRIEF-Clovis Oncology's Rucaparib Ariel3 study data published in The Lancet

* Clovis Oncology's Rucaparib Ariel3 study data published in The Lancet

13 Sep 2017

BRIEF-Clovis Oncology Q2 loss per share $3.88

* Clovis Oncology announces second quarter 2017 operating results

03 Aug 2017

BRIEF-Bristol-Myers, Clovis Oncology announce broad clinical collaboration

* Bristol-Myers Squibb and Clovis Oncology announce a broad clinical collaboration to evaluate combination of opdivo (nivolumab) and rubraca (rucaparib) in phase 2 and pivotal phase 3 clinical trials in multiple tumor types

31 Jul 2017

Competitors

  Price Chg
Eisai Co., Ltd (4523.T) ¥6,303 -145.00
Pfizer Inc. (PFE.N) $37.18 +0.58
AstraZeneca plc (AZN.L) 4,947.00 -43.50
BioMarin Pharmaceutical Inc. (BMRN.OQ) $89.64 --
TESARO Inc (TSRO.OQ) $61.86 --
AbbVie Inc (ABBV.N) $104.36 +1.87
Novartis AG (NOVN.S) CHF82.68 -0.56
Johnson & Johnson (JNJ.N) $146.98 +0.12
Eli Lilly and Co (LLY.N) $86.21 +0.92
GlaxoSmithKline plc (GSK.L) 1,344.80 -14.40

Earnings vs. Estimates